Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics
YMAB Price/Volume Stats
| Current price | $5.10 | 52-week high | $16.11 |
| Prev. close | $4.96 | 52-week low | $3.55 |
| Day low | $4.75 | Volume | 144,100 |
| Day high | $5.12 | Avg. volume | 345,130 |
| 50-day MA | $4.41 | Dividend yield | N/A |
| 200-day MA | $8.70 | Market Cap | 230.95M |
YMAB Stock Price Chart Interactive Chart >
Y-mAbs Therapeutics, Inc. (YMAB) Company Bio
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.
YMAB Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
YMAB Price Returns
| 1-mo | 31.44% |
| 3-mo | -1.16% |
| 6-mo | -51.61% |
| 1-year | -58.57% |
| 3-year | -61.91% |
| 5-year | -88.15% |
| YTD | -34.87% |
| 2024 | 14.81% |
| 2023 | 39.75% |
| 2022 | -69.90% |
| 2021 | -67.26% |
| 2020 | 58.43% |